logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
IONS
Ionis Pharmaceuticals, Inc.
79.19
2 x 72.46
2 x 85.32
bid
ask
-
0.10
0.13%
2 @ 04:00 PM
79.19 +0.00 (0.00%)
Ytd0.10%
1y98.27%
77.95
day range
79.48
39.86
52 week range
86.74
Open79.13Prev Close79.29Low77.95High79.48Mkt Cap13.09B
Vol1.43MAvg Vol1.82MEPS-2.01P/EN/AForward P/E-130.13
Beta0.37Short Ratio10.30Inst. Own107.26%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg75.32200-d Avg75.651yr Est105.91

IONS News

IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
zacks.com
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati

Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. comm

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
seekingalpha.com
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridem

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridem

FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
zacks.com
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia

Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market
benzinga.com
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $75

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutra

Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
benzinga.com
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk

The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.'s (NAS

Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
benzinga.com
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk

Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing
benzinga.com
Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $129

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe
benzinga.com
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $130

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

benzinga.com
Ionis Pharmaceuticals Announces License Agreement With Recordati For Zilganersen In Alexander Diseas

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access

benzinga.com
Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $122

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe
benzinga.com
TD Cowen Reiterates Buy on Ionis Pharmaceuticals, Maintains $108 Price Target

TD Cowen analyst Yaron Werber reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maint

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
benzinga.com
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and
benzinga.com
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $125 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)